Clinical Trials
14 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT04338399 2025-11-17
BURAN
Adlai Nortye Biopharma Co., Ltd.
Phase 3 Completed
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT06062602 2023-10-06
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Presage Biosciences
Phase EARLY_PHASE1 Completed
NCT00971867 2022-04-08
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT02051751 2020-12-08
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Novartis
Phase 1 Completed
NCT01911598 2017-07-06
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Genentech, Inc.
Phase 1 Completed
NCT02630264 2015-12-15
E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Guangzhou Double Bioproducts Co., Ltd
Phase 3 Unknown
NCT02283489 2014-11-05
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
Chengdu Shi Endor Biological Engineering Technology Co., Ltd
Phase 2 Unknown
NCT01701349 2014-05-01
FACT2
Mateon Therapeutics
Phase 3 Withdrawn
NCT01024101 2011-04-25
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00337532 2010-02-04
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00855764 2010-02-04
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer
Bristol-Myers Squibb
Phase 2 Completed